JAK2 and myeloproliferative neoplasm: Another way of assessing the therapeutic effects of selective JAK2 small-molecule inhibitors targeting the V617F point mutation is by ex vivo tests using primary cells derived from MPN patients carrying the JAK2V617F mutation.